ClearPoint Neuro (NASDAQ:CLPT) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

ClearPoint Neuro (NASDAQ:CLPT) released its quarterly earnings data on Wednesday. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.04), Zacks reports. The business had revenue of $12.13 million during the quarter, compared to analysts’ expectations of $11.97 million. ClearPoint Neuro had a negative net margin of 71.57% and a negative return on equity of 137.02%.

Here are the key takeaways from ClearPoint Neuro’s conference call:

• ClearPoint Neuro reported record Q1 2026 revenue of $12.1 million, up 43% year over year, with 16% organic growth driven by its core device businesses and the newly added IRRAflow line.
• Gross margin improved to 64% from 60% a year ago, helped by lower excess and obsolete inventory reserves and early benefit from the IRRAS integration.
• The company reaffirmed full-year 2026 revenue guidance of $52 million to $56 million and said sequential growth should continue through the rest of the year, though first-half timing may be uneven.
• Management highlighted progress across all four growth pillars, including new CAL facility studies, the first Asia-Pacific commercial drug delivery procedure, and expansion of the 3.x navigation platform into Europe and Canada.
• ClearPoint said it has successfully integrated IRRAflow operations and expects the business to become cash neutral as early as 2027, supported by cost synergies, facility consolidation, and broader commercial adoption.

ClearPoint Neuro Stock Performance

NASDAQ CLPT traded down $1.15 during mid-day trading on Friday, reaching $11.62. 371,295 shares of the stock were exchanged, compared to its average volume of 726,042. The business’s 50 day moving average is $10.44 and its 200-day moving average is $13.27. ClearPoint Neuro has a 1 year low of $8.27 and a 1 year high of $30.10. The company has a market capitalization of $348.44 million, a P/E ratio of -11.52 and a beta of 1.29. The company has a debt-to-equity ratio of 1.75, a quick ratio of 5.13 and a current ratio of 5.91.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CLPT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Monday, April 20th. Stifel Nicolaus began coverage on shares of ClearPoint Neuro in a report on Friday, May 8th. They issued a “buy” rating and a $16.00 price objective on the stock. Finally, B. Riley Financial upped their price objective on shares of ClearPoint Neuro from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, ClearPoint Neuro has an average rating of “Hold” and a consensus target price of $18.00.

Institutional Trading of ClearPoint Neuro

Hedge funds have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd purchased a new stake in ClearPoint Neuro during the fourth quarter worth $25,000. BNP Paribas Financial Markets boosted its holdings in ClearPoint Neuro by 2,435.2% during the second quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock worth $27,000 after buying an additional 2,143 shares in the last quarter. Legal & General Group Plc purchased a new stake in ClearPoint Neuro during the second quarter worth $35,000. Russell Investments Group Ltd. boosted its holdings in ClearPoint Neuro by 1,079.0% during the third quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock worth $51,000 after buying an additional 2,158 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in ClearPoint Neuro during the second quarter worth $80,000. 30.08% of the stock is owned by hedge funds and other institutional investors.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.